Obesity rise in Africa boosts weight loss drug market

The anticipated increase in obesity across Africa is creating new opportunities for manufacturers of weight loss drugs. This growing health concern is driving demand for medications like GLP-1 receptor agonists, which are widely used to manage weight and diabetes.

Global drugmakers target African expansion

Novo Nordisk and Eli Lilly, two leading manufacturers of obesity medications, are working to extend their South African success to the rest of the continent. They aim to capitalize on the rising demand for weight loss treatments as obesity rates climb.

Regulatory challenges complicate market growth

Despite the growing need, the expansion of these drugs faces regulatory hurdles. South Africa recently announced stricter rules on personalized preparations, which compete with products from major pharmaceutical companies. These preparations, often used for individualized treatment, are now under closer scrutiny.

GLP-1 drugs gain traction in South Africa

Novo Nordisk's Wegovy and Ozempic, and Lilly's Mounjaro are among the GLP-1 drugs gaining popularity in South Africa. These medications are primarily used to suppress appetite and aid weight loss, with some also approved for diabetes management. South Africa remains the primary market for these products on the continent.

Market growth in South Africa shows promise

The South African market for GLP-1 drugs, which include treatments for both diabetes and weight management, has nearly doubled in value. As of June 30, 2026, the market reached 2.8 billion rand (about 170 million dollars), showing strong growth and potential for further expansion.

Pharmaceutical companies expand regionally

Novo Nordisk has launched Wegovy and Ozempic in Kenya, while Egypt has approved Wegovy. Lilly's Mounjaro is also being considered for wider use, with registration applications submitted in Kenya and Nigeria. These moves indicate a strategic push to grow the market across Africa.

Africa's obesity crisis fuels demand

The rise in obesity across Africa is linked to lifestyle changes, including dietary shifts and increased sedentary behavior due to urbanization. According to the World Health Organization, obesity rates among adults in Africa rose from 8.64% in 2010 to 12.08% in 2022, signaling a growing need for effective treatments.

Market potential extends beyond initial use

The demand for obesity drugs is not limited to short-term weight loss. It also supports long-term treatments to maintain weight loss, which is crucial for managing chronic conditions. Globally, the obesity drug market is projected to grow significantly, from 66 billion dollars in 2025 to over 200 billion dollars by 2027.

High costs limit accessibility

Despite the growing demand, the high cost of these drugs remains a barrier. In South Africa, the most concentrated version of Wegovy costs 3,746 rand for four weeks, which is more than three-quarters of the gross salary earned by an employee working 40 hours per week at the legal minimum wage. This cost issue is also evident in Western markets, where many users struggle with affordability.

Competition and counterfeit drugs pose risks

The market is becoming more competitive, with generic versions of GLP-1 drugs entering the scene. Sun Pharma, for example, launched a generic version of semaglutide in South Africa. Additionally, the circulation of counterfeit drugs, such as fake Ozempic, has raised concerns among regulators and manufacturers.

Regulatory clarity and new markets ahead

As the market evolves, regulatory clarity will be key. South Africa is set to publish new standards in March 2027, which may define the scope for personalized preparations. Elsewhere on the continent, the approval of new markets will depend on regulatory decisions and the actual launch of products.